key: cord-0802288-u5rx6rav authors: Kapur, Anil; Hod, Moshe title: Maternal health and non‐communicable disease prevention: An investment case for the post COVID‐19 world and need for better health economic data date: 2020-06-02 journal: Int J Gynaecol Obstet DOI: 10.1002/ijgo.13198 sha: 1681d470f651d5b1bb3a0513c85f223d35ec5861 doc_id: 802288 cord_uid: u5rx6rav An integrated approach to population health, disease surveillance, and preventive care will dominate the health agenda in the post COVID‐19 world. Because of their huge burden and the vulnerability imposed during a health crisis, prevention and care of non‐communicable diseases (NCDs) will need to be prioritized even further. Maternal and child health are inextricably linked with NCDs and their risk factors. The intergenerational impact of poor maternal nutrition and health conditions during pregnancy, particularly NCD‐related pregnancy complications, can be considered as a multiplier of the ongoing pandemic of NCDs. The economic cost of poor maternal health and NCD‐related pregnancy complications is likely very high, but is not adequately researched or documented in the context of long‐term population health. Interventions to address NCDs in pregnancy have beneficial effects on short‐term pregnancy outcomes; but even more importantly, identifying “at‐risk” mothers and offspring opens up the opportunity for targeted early preventive action. Preventive actions to address obesity, hypertension, type 2 diabetes, and cardiovascular diseases have a common lifestyle approach—identifying any one of these problems in pregnancy provides an opportunity to address them all. Cost–benefit analyses that only focus on the short‐term and on one condition do not capture the full value of downstream, long‐term benefits for population health. This requires urgent attention from FIGO. the majority are the consequence of poor health due to the underlying comorbidity. NCDs are widely prevalent and, even in normal times, directly or indirectly account for most deaths (often premature) worldwide. In the post COVID-19 world, prevention and care of NCDs will have to be prioritized even further to improve population health; and what better place to begin than when life begins. Maternal and child health is inextricably linked with NCDs and their risk factors. Specifically, conditions such as prenatal malnutrition and low birth weight create a predisposition to obesity, type 2 diabetes, hypertension, and heart disease later in life. Furthermore, maternal overweight and obesity, gestational hypertension and pre-eclampsia, and gestational diabetes are associated with a higher risk for the above conditions in both the mother and offspring. Poor maternal nutrition and health during pregnancy may be considered as a multiplier of the ongoing pandemic of NCDs, particularly in low-resource countries, since it provides a crossover bridge for undernutrition in one generation to transit to overweight and obesity in the next generation through gestational hyperglycemia and macrosomia; thereby impacting subsequent generations with overweight, obesity, type 2 diabetes, and cardiovascular diseases among others. 3 Poor maternal health increases the risk of NCDs in the offspring, and in subsequent generations NCDs lead to poor maternal health, setting a vicious cycle of intergenerational risk transmission through developmental programming. 4 Of the approximately 130 million pregnancies resulting in live births globally every year, an estimated 21 million are impacted by hyperglycemia, about 7-8 million by hypertension, about 42 million by maternal overweight and obesity, 26 million by maternal undernutrition, and 56 million by maternal anemia. 5 Not only do these conditions increase the risk of adverse pregnancy outcomes and increase perinatal morbidity and mortality, but they also identify both the mother and the offspring at high risk for future diabetes, obesity, hypertension, cardiovascular disease, and stroke. Medical conditions that are exacerbated by pregnancy, such as obesity, diabetes, cardiovascular disease, among others, already account for over 28% of maternal deaths worldwide, 6 with the number only likely to increase further over time. They also impact fetal growth (intrauterine growth restriction, small for gestational age, macrosomia and large for gestational age) and increase the risks of prematurity, stillbirth, congenital malformations, birth injuries, respiratory distress, and hypoglycemia, among others, at birth. The economic cost of NCDrelated pregnancy complications is likely very high, but is unfortunately not adequately researched nor documented. Overweight and obesity in pregnancy not only cause problems of their own but also increase the risk of hyperglycemia, hypertension, and pre-eclampsia. Similarly, hyperglycemia in pregnancy increases the risk of hypertension and pre-eclampsia, thereby compounding adverse pregnancy outcomes. While there are studies addressing the costs of individual NCDs, their combined impact associated with causing pregnancy complications and compounding costs has rarely been studied, despite the clear interconnectedness. The presence of these conditions during pregnancy is a reliable marker for future NCDs in both the mother and offspring. Thus, overweight or obese pregnant women without gestational diabetes or gestational hypertension continue to be at high risk for future type 2 diabetes, hypertension, and cardiovascular disease later in life. Similarly, women with gestational diabetes, apart from being at very high risk of type 2 diabetes, are at high risk of future hypertension and cardiovascular disease, as are women with gestational hypertension and pre-eclampsia. In addition, the offspring of pregnancies impacted by any of these NCDs are also at risk of obesity and cardiometabolic problems. Interventions to address NCDs in pregnancy have beneficial effects on the short-term pregnancy outcomes. Whether treatment during pregnancy will prevent or reduce long-term maternal and offspring risks is currently unknown and requires further well-designed, longterm intervention studies. Nonetheless, identifying "at risk" mothers and offspring opens up the opportunity for targeted early preventive action, which has been shown to be beneficial for some conditions such as gestational diabetes (described later). Since preventive actions to address obesity, hypertension, type 2 diabetes, and cardiovascular diseases have a common lifestyle approach, identifying any one of these problems in pregnancy provides an opportunity to address them all. Cost-benefit analyses that only focus on the short term and one condition do not capture the full value of downstream, long-term benefits for population health. Hyperglycemia is now one of the most common medical conditions seen during pregnancy. The International Diabetes Federation (IDF) estimates that 21 million live births (1 in 6 or 16.8%) occur in women with some form of hyperglycemia in pregnancy (HIP), of which 2.5% may be due to overt diabetes in pregnancy. 7 The other 14.3% (1 in 7 pregnancies) is due to gestational diabetes mellitus (GDM), a condition that may reflect pre-existing prediabetes or develop due to hormonal changes of pregnancy and is confined to the duration of pregnancy. 7 HIP significantly increases the risk of pregnancy complications such as hypertension, pre-eclampsia, stillbirth, premature delivery, both large-and small-for-gestational-age babies, obstructed labor, postpartum hemorrhage, infections, birth injuries, congenital anomalies, and newborn deaths due to respiratory problems, hypoglycemia, etc. Available evidence shows that HIP is associated with a high risk of maternal and perinatal morbidity and mortality and poor pregnancy outcome. [8] [9] [10] It has also been shown that women with a history of GDM are at a high risk of future diabetes and cardiovascular disease. [11] [12] [13] Offering these women postpartum lifestyle intervention and treatment prevents or delays the onset of diabetes and cardiovascular disease, 14-16 thus providing a unique opportunity for primary prevention of these conditions. In addition, the offspring of GDM pregnancies are at high risk of metabolic problems 17, 18 including early onset type 2 diabetes. 19 Treatment of maternal diabetes is expected to reduce these risks; however, there is still limited evidence from high-quality studies. 20,21 There are only a few studies that have evaluated the cost-effectiveness of an integrated approach to GDM screening and care that also Another US study reported that each case of GDM is associated with US $5800 in higher medical expenditures. 30 The overall health and economic costs associated with unrecognized and untreated GDM will undoubtedly be several fold higher, underscoring the importance of screening for and management of GDM. Evidence from prospective studies demonstrates that lifestyle and pharmacological interventions for prevention of diabetes are as effective in women with GDM as in non-GDM women with impaired glucose tolerance (IGT) and men with IGT. 14-16 A recent study showed that not only does metformin treatment continue to exert its diabetes prevention effect 15 years after randomization in the Diabetes Outcomes Study (DPPOS), but its effect was also significantly better in women with a history of prior GDM compared with parous women with IGT without previous GDM. 32 Breast feeding for more than 10 months has also been reported to decrease the risk of diabetes mellitus 2 years after delivery by 57% in women with a history of GDM. 33 Given that lifestyle interventions or use of medications for prevention of diabetes in people at risk in various settings are regarded as highly cost-effective and that treatment of GDM is cost-effective in preventing perinatal complications, it seems intuitive that screening and comprehensive care for GDM should be highly cost-effective overall, even in the absence of more cost-effectiveness data. 29 Complications of overweight and obesity during pregnancy include hypertensive disorders, coagulopathies, GDM, respiratory problems, and fetal complications such as large-for-gestational-age babies, congenital malformations, stillbirth, and shoulder dystocia. Risk of pre-eclampsia increases 2-3-fold in women overweight in early pregnancy. 34 Obesity is associated with an increased risk of maternal and instrument-assisted delivery (aOR 1.17). 36 Maternal overweight and obesity (body mass index [BMI] greater than 25, calculated as weight in kilograms divided by the square of height in meters) is the most important modifiable risk factor for stillbirths in high-income countries, contributing to around 8000 stillbirths (22 weeks of gestation) annually. 37 In low-income countries, apart from stillbirths, complications relate to the 2-3-fold increased risk of macrosomia, requiring institutional and assisted delivery. When these services are not available, significantly higher maternal morbidity and mortality may ensue. 38 Very few studies have assessed the economic costs of overweight and obesity associated with pregnancy. It has been estimated that the total costs for overweight and obese pregnant women with GDM during pregnancy and up to 2 months following delivery increase by 23% and 37%, respectively, compared with women with normal BMI. 39, 40 Infant healthcare usage cost is also linked to maternal BMI. Total mean additional cost, in a study from within the National Health Service in the UK, was estimated at £65.13 for infants born to overweight mothers and £1138.11 for infants born to obese mothers, when compared with infants of healthy weight mothers. 41 Hypertension is a significant contributor to pregnancy-related complications. It can occur as gestational hypertension, pre-eclampsia, chronic hypertension, or pre-eclampsia superimposed on chronic hypertension. Although the incidence varies in different parts of the world, overall, nearly 10% of normotensive women experience abnormally elevated blood pressure at some point during pregnancy. Hypertensive disorders of pregnancy (HDP) complicate 5%-10% of pregnancies and are increasing with the rising prevalence of overweight, obesity, diabetes, and metabolic disorders in younger, women of reproductive age. 42 Worldwide, high blood pressure with or without proteinuria is a major cause of maternal morbidity and mortality 43 and HPDs account for 10%-15% of maternal deaths in low-and middleincome countries, [44] [45] [46] as well as to increased perinatal morbidity and mortality as a consequence of prematurity and poor fetal growth. Pre-eclampsia typically affects 2%-5% of pregnant women and is one of the leading causes of maternal and perinatal morbidity and mortality, especially when the condition is early onset 47,48 ; globally, 76 000 women and 500 000 babies die each year from this disorder. 49 Furthermore, women in low-income countries are at a higher risk of developing pre-eclampsia compared with those in high-income countries. 50 Women who develop gestational hypertension and pre-eclampsia have a greater chance of developing cardiovascular disease and type 2 diabetes in later life. 51 Despite this, they do not routinely receive long-term follow-up, 52 counseling, or risk factor stratification and evaluation. Compared with an uncomplicated pregnancy, costs associated with pre-eclampsia are significantly higher, for both the mother and the neonate, in any given regional setting. This is because of Use of low-dose aspirin to prevent pre-eclampsia in women at risk is well accepted and the ASPRE trial conclusively proved its value in preventing preterm pre-eclampsia. 57 The findings have implications for both short-and long-term healthcare costs as well as infant survival and handicap. 58 Using a decision analysis model, the clinical and economic benefits of a first-trimester screening program based on the Fetal Medicine Foundation algorithm for prediction of early-onset pre-eclampsia coupled with early (<16 weeks) use of low-dose aspirin in those at high risk was simulated and tested with current practice in Canada. 59 From a large-scale program perspective, there are two key challenges in effectively improving pregnancy outcomes, particularly in low-and low/middle-income countries. First is the inability of health systems to screen women for common medical conditions that create pregnancy complications early enough (preconception, first trimester), to identify women requiring treatment and preventive care. The second is the inability to track and follow up women with an NCD-related pregnancy complication after delivery to continuously engage and empower the at-risk mother-child pair to adopt a healthy lifestyle. 66 Without adequate focus on postpartum care, the strategy for screening and treatment of common NCDs during pregnancy is only half as effective. Focusing only on the short-term survival in terms of lowered maternal and perinatal morbidity and mortality does not capture outcomes that have longer-term implications for adult health, life expectancy, quality of life, and accumulation of human capital. 67 Pregnancy offers a window of opportunity to provide maternal care services, not only to reduce the traditionally known maternal and perinatal morbidity and mortality indicators, but also for intergenerational prevention of several chronic diseases. 68 Multiple barriers stand in the way of these objectives. The barriers related to GDM, for example, have been described in a systematic review 69 and efforts should be made to mitigate these barriers to achieve program objectives. A 2007 publication by Abegunde et al. 70 noted that the estimated age-standardized death rate from chronic diseases in 23 low-income and middle-income countries with 80% of the global NCD burden was higher (54%) for men and even higher (86%) for women compared with those in high-income countries. In 2014, Stenberg et al. 71 Despite the clear logic and some health economic evidence, why is it that the link between maternal health and prevention of NCD is continually neglected? Perhaps the silo approach to health that divides healthcare delivery into communicable and non-communicable diseases and maternal and child health is partly responsible. This division extends even within maternal child care, such that long-term postpartum follow-up of women with demonstrated pregnancy complications is not linked to the child's follow-up and vaccination program, which provides an opportunity to track the high-risk mother-child pair. The other reason is perhaps that the health economic impact of addressing overall maternal health is addressed merely in terms of the short-term outcomes of different conditions and not in the integrated longer-term impact on future population health when combined with continued tracking, engaging, and empowering for healthy lifestyles. 66 As the global voice for women's health, FIGO needs to give urgent attention to this area, in particular creating health economic evidence for an integrated approach to maternal health and NCD prevention. When health system priorities are reconfigured in the post-COVID-19 world, the "silo mentality" will have to be broken down to transform health systems. What better place to begin the transformation than where life begins, ensuring the health of women before, during, and after pregnancy and of their offspring in a life course approach that is not merely theoretical but pragmatic and economical to society-an approach that documents, tracks, empowers, and proactively engages reproductive-age people and their offspring for good health. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States Comorbidities the rule in New York's COVID-19 deaths. The Hospitalist Take home message: Start where life begins and follow the life-course approach Non-industrialised countries and affluence Links between maternal health and NCDs Trends in Maternal Mortality: 1990 to 2013. Estimates by WHO, UNICEF, UNFPA, The World Bank and the United Nations Population Division. Geneva: WHO International Diabetes Federation. IDF Diabetes Atlas 7th Edition Atlantic diabetes in pregnancy (DIP): The prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria Gestational diabetes and pregnancy outcomes-a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria Macrosomia in 23 developing countries: An analysis of a multicountry, facility-based, cross-sectional survey Type 2 diabetes mellitus after gestational diabetes: A systematic review and meta-analysis Mild glucose intolerance in pregnancy and risk of cardiovascular disease: A population-based cohort study An association between gestational diabetes mellitus and long-term maternal cardiovascular morbidity Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: Effects of metformin and lifestyle interventions Physical activity and sedentary behaviors associated with risk of progression from gestational diabetes mellitus to type 2 diabetes mellitus: A prospective cohort study for the Diabetes Prevention Program Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: The diabetes prevention program outcomes study 10-year follow-up Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: The SEARCH Case-Control Study High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: The role of intrauterine hyperglycemia Association between maternal diabetes in utero and age at offspring's diagnosis of type 2 diabetes Childhood obesity and metabolic imprinting: The ongoing effects of maternal hyperglycemia Does exposure to hyperglycaemia in utero increase the risk of obesity and diabetes in the offspring? A critical reappraisal The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: Application of a new model in India and Israel Screening for gestational diabetes mellitus: Are the criteria proposed by the international association of the Diabetes and Pregnancy Study Groups cost-effective? Diabetes Care Treating patients in HAPO glucose category 5 to improve maternal and neonatal outcomes: A cost effectiveness analysis Treating mild gestational diabetes mellitus: A cost-effectiveness analysis Australian Carbohydrate Intolerance Study in Pregnant Women Group. Costs and consequences of treatment for mild gestational diabetes mellitus -evaluation from the ACHOIS randomised trial Cost-Effectiveness Analysis of Gestational Diabetes Mellitus Screening in Urban Chinese Setting The short-term health and economic burden of gestational diabetes mellitus in China: A modelling study Health economic modeling to assess short-term costs of maternal overweight, gestational diabetes, and related macrosomia-a pilot evaluation The economic burden of elevated blood glucose levels in 2017: Diagnosed and undiagnosed diabetes, gestational diabetes, and prediabetes Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States Long-term effects of metformin on diabetes prevention: Identification of subgroups that benefited most in the diabetes prevention program and diabetes prevention program outcomes study Lactation and progression to type 2 diabetes mellitus after gestational diabetes mellitus: A prospective cohort study Risk factors for preeclampsia in healthy nulliparous women: A prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units The impact of maternal BMI status on pregnancy outcomes with immediate short-term obstetric resource implications: A meta-analysis Extreme obesity in pregnancy in the United Kingdom Major risk factors for stillbirth in high-income countries: A systematic review and meta-analysis Macrosomia in 23 developing countries: An analysis of a multicountry, facility based, cross-sectional survey Association between maternal body mass index during pregnancy, short term morbidity, and increased health service costs: A population-based study Modelling the independent effects of gestational diabetes Mellitus on maternity care and costs Obesity in pregnancy: Infant health service utilization and costs on the NHS Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1988-1990. London: HMSO Maternal deaths due to hypertensive disorders in pregnancy: Saving mothers report 2002-2004 Maternal deaths due to hypertensive disorders in pregnancy Maternal mortality due to eclamptic and noneclamptic hypertensive disorders: A challenge Eclampsia and pre-eclampsia: A health problem for 2000 years Maternal mortality: Who, when, where, and why Hypertensive disorders and severe obstetric morbidity in the United States The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention Pregnancy-induced hypertension and diabetes and the risk of cardiovascular disease, stroke, and diabetes hospitalization in the year following delivery The maternal health clinic: An initiative for cardiovascular risk identification in women with pregnancy-related complications Costs of Gestational Hypertensive Disorders in California: Hypertension, Preeclampsia, and Eclampsia Estimating the cost of preeclampsia in the healthcare system: Cross-sectional study using data from SCOPE Study (screening for pregnancy end points) Birth hospitalization costs and days of care for mothers and neonates in California Short-term costs of preeclampsia to the United States health care system Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia Aspirin for evidence-based preeclampsia prevention trial: Effect of aspirin on length of stay in the neonatal intensive care unit The cost effectiveness of first trimester screening and early preventative use of aspirin in women at high risk of early onset pre-eclampsia Economic assessment of screening for pre-eclampsia Financial impact of a novel preeclampsia diagnosis test versus standard practice: A decision-analytical modelling analysis from a UK healthcare payer perspective Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany Economic evaluation of sFlt-1/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals Methods of prediction and prevention of pre-eclampsia: Systematic reviews of accuracy and effectiveness literature with economic modelling Pregnancy a window of opportunity for improving current and future health Towards a new developmental synthesis: Adaptive developmental plasticity and human disease World Diabetes Foundation. Global Alliance for Women's Health. Diabetes, women, and development. Meeting, expert recommendations for policy action, conclusions, and follow-up actions From screening to postpartum follow-up -the determinants and barriers for gestational diabetes mellitus (GDM) services, a systematic review The burden and costs of chronic diseases in low-income and middle-income countries Advancing social and economic development by investing in women's and children's health: A new Global Investment Framework Investing in non-communicable diseases: An estimation of the return on investment for prevention and treatment services AK wrote the first draft, which was reviewed and commented by MH.Both authors contributed to the final article. The authors have no conflicts of interest.